Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06234397 | Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | PHASE1 | RECRUITING | 245 | — | — | Dec 28, 2023 | Jan 1, 2028 | Mar 11, 2026 | 10 | United States, South Korea |
To evaluate safety and tolerability of BH3120 as a single agent and in combination with pembrolizumab administration
To evaluate safety and tolerability of BH3120 as a single agent and in combination with pembrolizumab administration
| Arm | Type | Description |
|---|---|---|
| BH3120 | EXPERIMENTAL | Arm A: BH3120 Monotherapy |
| BH3120 + pembrolizumab | EXPERIMENTAL | Arm B: BH3120 in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| BH3120 | DRUG | BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle |
| pembrolizumab | DRUG | Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle |
Key Inclusion Criteria: * Have a Histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy. * PD-L1 positive expression (Tumor Proportion Score ≥1% or Combined Positive Score ≥1). * Have at least one lesion, ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |